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Background: Hypercoagulability, assessed by the thrombelastography (TEG) assay, has in several observational
studies been associated with an increased risk of post-procedural thromboembolic complications. We hypothesize
that intensified antiplatelet therapy with clopidogrel and aspirin, as compared to aspirin alone, will improve
saphenous vein graft patency in preoperatively TEG-Hypercoagulable coronary artery bypass surgery (CABG) patients
and reduce their risk for thromboembolic complications and death postoperatively.
Methods/Design: This is a prospective randomized clinical trial, with an open-label design with blinded evaluation
of graft patency. TEG-Hypercoagulability is defined as a TEG maximum amplitude above 69 mm. Two hundred and
fifty TEG-Hypercoagulable patients will be randomized to either an interventional group receiving clopidogrel 75
mg daily for three months (after initial oral bolus of 300 mg) together with aspirin 75 mg or a control group
receiving aspirin 75 mg daily alone. Monitoring of antiplatelet efficacy and on-treatment platelet reactivity to
clopidogrel and aspirin will be conducted with Multiplate aggregometry. Graft patency will be assessed with
Multislice computed tomography (MSCT) at three months after surgery.
Conclusions: The present trial is the first randomized clinical trial to evaluate whether TEG-Hypercoagulable CABG
patients will benefit from intensified antiplatelet therapy after surgery. Monitoring of platelet inhibition from
instituted antithrombotic therapy will elucidate platelet resistance patterns after CABG surgery. The results could be
helpful in redefining how clinicians can evaluate patients preoperatively for their postoperative thromboembolic risk
and tailor individualized postoperative antiplatelet therapy.
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Coronary artery bypass surgery (CABG) is conducted in
approximately one million patients a year worldwide.
The success of the operation is highly dependent on the
vascular bypass remaining open. Saphenous vein graft
(SVG) is the most commonly used bypass conduit [1].
SVG occlusion is reported from 5% to 15% within the
first year [1,2]. Thrombosis of the SVG is the primary
reason for occlusion in the first days and weeks after sur-
gery; hereafter the processes of intimal hyperplasi and
progressive graft atheroschlerosis are assumed to grad-
ually play a greater role in graft occlusion [3,4].Hypercoagulability and thromboembolic risk
Recent observational studies have shown an association
between hypercoagulability measured by thrombelasto-
graphy (TEG) defined by increased thrombin-induced
platelet-fibrin clot strength (TEG-Hypercoagulable) and
postoperative/post-interventional thromboembolic com-
plications. Gurbel and colleagues reported that in
patients undergoing percutaneous coronary intervention
(PCI), 60% of TEG-Hypercoagulable patients developed
an ischemic event post-intervention, while this only was
the case in 9% of TEG-Normocoagulable patients,
P<0.0001 [5]. Another observational study in patients
undergoing major non-cardiac surgery found that 8 out
of 95 (8.4%) of TEG-Hypercoagulable patients had a
postoperative thromboembolic complication, while only
2 out of 145 (1.4%) TEG-Normocoagulable patients
experienced thromboembolic episodes, P= 0.016 [6].
Also, in critically ill patients in the surgical intensive care
unit, TEG-Hypercoagulable status has been demon-
strated to yield a significantly greater risk for thrombo-
embolic complications [7]. Our group has conducted a
prospective observational study of 200 consecutive
CABG patients, and found that TEG-hypercoagulability
(defined as TEG maximum amplitude (MA) above 69
mm) was prevalent in 87 patients (43.5%) before surgery,
and preoperative TEG-Hypercoagulable patients had a
higher risk of a combined endpoint of myocardial infarc-
tion (MI), stroke and death after 30 days, as compared to
TEG-Normocoagulable patients, 17.2% vs. 6.6%,
P= 0.019 [8].
Based on the above findings it could be speculated
whether TEG-Hypercoagulable patients may benefit
from intensified antiplatelet therapy to reduce thrombo-
embolic risk after surgery/intervention.
Furthermore, it has been demonstrated that surgery itself
induces hypercoagulability, both after CABG and major
non-cardiac surgery [6,9]. Our study will help elucidate if
the extent of this increase in patients who are already TEG-
hypercoagulable preoperatively, is an independent risk
factor.Antiplatelet therapy after CABG
Antiplatelet therapy with aspirin is well established
after CABG. Graft occlusion rates in the 1980s were
reduced from 20 to 30% in the first year after surgery
to 10 to 15%, if aspirin therapy was restarted 6 to 24
hours after surgery [3]. Clopidogrel is a thienopyridine
antiplatelet agent that inhibits adenosine diphosphate
(ADP)-receptors on the platelet surface (P2Y12 recep-
tors), thereby reducing platelet activation and aggrega-
tion [10]. Dual antiplatelet therapy with clopidogrel in
addition to aspirin is well established in the treatment
of acute coronary syndromes and in PCI patients, and
has been shown to significantly reduce cardiovascular
events and death as compared to aspirin treatment
alone in these patients [10-12]. However, these studies
have also reported that dual antiplatelet therapy signifi-
cantly increases bleeding risk [10-12].
The role of dual antiplatelet therapy after CABG is still
not clear. Current guidelines from the European Society
of Cardiology (ECS) and European Association of Car-
dioThoracic Surgeons (EACTS) recommend dual anti-
platelet therapy in acute coronary syndrome patients
after CABG [13]. These recommendations are primarily
based on the “Clopidogrel in Unstable angina to prevent
Recurrent ischemic Events” (CURE) and “Clopidogrel
Versus Aspirin in Patients at Risk of Ischemic Events”
(CAPRIE) trials [12,14]. It should be noted though, that
the subgroup study of the CURE trial failed to demon-
strate any beneficial effect of clopidogrel after CABG
[14]. Furthermore, the CAPRIE investigators performed
a subgroup analysis of patients who have had prior car-
diac surgery, but did not stratify for different types of
procedures (valve surgery, CABG and so on) and also
did not take time from surgery to inclusion in the study
(up to years) into consideration [12]. Consequently, these
data do not support the routine use of clopidogrel in
addition to aspirin after CABG in patients with acute
coronary syndrome undergoing surgical revasculariza-
tion, and this has been corroborated by a recent
Cochrane review [15].
No randomized trial to date has examined the role of clo-
pidogrel after cardiac surgery in acute coronary syndrome
patients. The randomized trials have focused on the CABG
patient population as a whole. Last year the long awaited
“Clopidogrel After Surgery for Coronary Artery Disease”
(CASCADE) trial was published. The primary endpoint fo-
cused on potentially reduced SVG intimal hyperplasi in
patients on dual antiplatelet therapy (clopidogrel and as-
pirin) as compared to aspirin and placebo therapy. As a sec-
ondary endpoint, SVG patency was also examined. The
study did not demonstrate significant differences among
antiplatelet regimens [16]. “The Preoperative Aspirin and
Postoperative Antiplatelets in Coronary Artery Bypass
Grafting” (PAPA-CABG) trialists have published pilot data
Table 1 Inclusion/exclusion criteria
Inclusion Criteria
• Elective/subacute multivessel CABG
• Isolated CABG procedure, no concomittant surgery
• Age >18 years
• Able to give informed consent
Exclusion Criteria
• Myocardial infarction <48 h of surgery
• Prior CABG surgery within one month
• Cardiac Shock within 48 h of surgery
• Atrial fibrillation
• Anticoagulation therapy with VKA
• ICH/TCI within 30 days
• Prior peptic ulcer
• Platelet count <150 E9
• Ongoing bleeding
• Known platelet disease
• Allergic to aspirin or clopidogrel
• Liver disease with elevated ALAT/ASAT >1.5x normal
• Creatinine >0.120 mmol/l
• Contrast allergy
• Alcohol or narcotics abuse
• Pregnancy
• Geographically not available for follow-up
This table shows the inclusion and exclusion criteria in the TEG-CABG trial.
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aspirin vs. aspirin alone, reporting no difference in SVG pa-
tency at 30 days measured by cardiac computed tomog-
raphy [17]. Gurbuz and associates have published data from
591 consecutive off-pump coronary artery bypass surgery
procedures performed by one surgeon. There was no
randomization but historical controls. They demonstrated a
significant positive clinical effect of dual antiplatelet therapy
on the endpoints of postoperative MI and death [18]. Gao
and colleagues published data from a randomized clinical
trial in 2010 showing that SVG patency assessed by multi-
slice computed tomography (MSCT) three months after
CABG showed significant improvement in SVG patency in
patients receiving dual antiplatelet therapy with clopidogrel
and aspirin vs. aspirin alone, 92% vs. 86%, P=0.043 [19].
High on-treatment platelet reactivity and thromboembolic
risk
In recent years, there has been a growing acknowledge-
ment of the association between insufficient platelet inhib-
ition from instituted antiplatelet therapy (that is,
clopidogrel and/or aspirin) and thromboembolic complica-
tions. Studies in PCI patients have demonstrated a signifi-
cantly higher risk for post-procedure thromboembolic
episodes in individuals that demonstrate high on-
treatment platelet reactivity to ADP [3,20-22]. Few studies
have demonstrated that after conventional CABG with
cardio-pulmonary bypass up to 50% of the patients will be
transiently aspirin resistant, and this high on-treatment
platelet reactivity has been correlated to early SVG throm-
bosis after CABG [3,23]. The platelet reactivity patterns of
clopidogrel after cardiopulmonary bypass have not been
examined. We will monitor platelet reactivity in our trial
to elucidate the patterns and degree of high on-treatment
platelet reactivity of aspirin and clopidogrel in the immedi-
ate postoperative period and three months after CABG.
Hypothesis
We have asked the following research questions: Can inten-
sified antiplatelet therapy with the addition of clopidogrel to
aspirin as compared to routine aspirin monotherapy signifi-
cantly improve graft patency at three months in TEG-
Hypercoagulable patients? Can dual antiplatelet therapy sig-
nificantly reduce the heightened risk for thromboembolic
complications and cardiovascular death in TEG-Hypercoa-
gulable patients? Does failure of instituted antiplatelet ther-
apy to inhibit platelet aggregation increase patients risk for
SVG occlusion and thromboembolic events after CABG?
Methods/Design
Study population
Patients over the age of 18 referred to our tertiary insti-
tution (Department of Cardio-thoracic Surgery, Rig-
shospitalet, Copenhagen University Hospital, Denmark)for isolated non-emergent CABG procedure were
screened for eligibility. See inclusion/exclusion criteria
in Table 1. Patients are enrolled from November 2008
to March 2013.Design and randomization procedure
The TEG-CABG trial is a prospective open label, rando-
mized clinical trial with blinded evaluation of the pri-
mary endpoint (graft patency evaluation by 320 slice-
MSCT). Figure 1 shows a flowchart of the study.
The study nurse, utilizing the sealed envelope tech-
nique, randomizes 250 TEG-Hypercoagulable (TEG MA
>69 mm) patients on the day before CABG, allocating
125 patients to the interventional group (receiving clopi-
dogrel for three months and lifelong aspirin) and 125
TEG-Hypercoagulable patients to a control group (re-
ceiving lifelong aspirin only).
TEG, Multiplate aggregometry and routine blood sam-
ples are obtained the day before surgery, on Day 4 after
CABG, and at three months postoperatively.
MSCT is conducted at three months after surgery.
Figure 1 Study flow chart.
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All CABG procedures are performed through median
sternotomy. At our institution approximately 97% of
CABG procedures are performed on-pump with cardio-
pulmonary bypass and extracorporal circulation (ECC).
Patients on ECC are heparinised to maintain an acquired
coagulation time (ACT) above 480s, and this is reversed
with protaminesulphate (1:1) after finalization of ECC.
All patients on ECC receive a total of four grams tranex-
amic acid during surgery.
The left internal mammarian artery (LIMA) is the pre-
ferred conduit for anastomoses to the left anterior des-
cending artery (LAD), for all other anastomoses SVG
conduits are preferred.There is no specific team assigned or any restrictions
of cardiac surgeons and/or anesthetists to perform pro-
cedures on patients in this trial.
Perioperative anticoagulation
Routinely, aspirin and clopidogrel are discontinued five
days before surgery. In patients with acute coronary syn-
drome 40 mg of Clexane (enoxaparin- a low-molecular-
weight heparine (LMWH)) twice daily or 2.5 mg of Arixtra
(Fondaparinux) once daily is administered subcutaneously
until the day before surgery. After surgery, only off-pump
patients received Clexane 40 mg s.c. twice daily until dis-
charged from hospital, all other patients do not receive
LMWH after CABG.
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Aspirin 75 mg is restarted within 24 hours of surgery, in
accordance with the current recommendations from
ECS/EACTS [13]. In the intervention group clopidogrel
is started at Day 2 after surgery, with a 300 mg oral bolus
to achieve greater initial platelet inhibition [24,25].
Thereafter, clopidogrel therapy is continued with a daily
dose of 75 mg for 90 days. Our study is the first study in
CABG patients to utilize initial oral bolus of 300 mg clo-
pidogrel. Greater loading doses of clopidogrel (that is,
600 mg) were not utilized due to bleeding concerns - in
particular GI bleeding - in the postoperative setting,
expressed by the cardiac surgeons at our institution.
Patients will receive study medication (clopidogrel)
from the study nurse for the whole study period. At
three months the patients are requested to bring in their
remaining medication, so compliance can be assessed.
Outcome measures
Primary:
Graft patency assessed at three months by MSCT will
be significantly improved in TEG-Hypercoagulable
patients allocated to dual antiplatelet therapy with
clopidogrel and aspirin as compared to aspirin alone.
Secondary:
1. TEG-Hypercoagulable patients will suffer fewer
thromboembolic events (that is, MI, stroke,
pulmonary embolism, gastrointestinal ischemia, deep
vein thrombosis) or cardiovascular death when on
clopidogrel and aspirin vs. aspirin alone.
2. Assess if the degree of surgically induced
hypercoagulability itself is an independent factor of
graft occlusion, thromboembolic events and death.
3. High on-treatment platelet reactivity in spite of
Aspirin and/or clopidogrel treatment, as evaluatedFigure 2 TEG tracing.by Multiplate aggregometry, increases the risk of
thromboembolic events after CABG surgery.
All outcome measures will be evaluated at three
months postoperatively.
Thrombelastography (TEG)
Until recently, detection of platelet hyper-reactivity
demanded sophisticated and time consuming assays. With
the modernization and computerization of the TEG meth-
odology, it has gained more clinical interest in specialities
beyond cardiac and liver surgery, in which TEG analysis
has been used to guide transfusion regimens since the
1980s [26]. TEG measures kinetics of clot formation, clot
strength, platelet function and fibrinolysis, and thus pro-
vides a global picture of the patient’s hemostatic ability
and the viscoelastic properties of the clot [26,27]. The ana-
lysis is performed on whole blood, in contrast to routine
plasma-based coagulation tests [26]. For TEG-analysis,
whole blood is collected in a 3.2% trisodium citrate vacu-
tainer (Greiner Bio-One, Kremsmünster, Austria) and ana-
lyzed within 90 minutes after collection by use of a
computerized TEG coagulation analyser (TEG model
5000, Haemoscope Corporation, Niles, IL, USA), but not
earlier than 30 minutes after collection.
In the TEG analyser, whole blood is incubated in a
heated cup (37°C). Within the cup a torsion wire, which
can monitor movement, is suspended. In our series we
utilize kaolin as a potent initiator of coagulation other acti-
vators of coagulation can be used [23]. The cup starts rota-
tion, and as fibrin forms between the cup and the pin, the
rotation is transmitted from the cup to the pin, and the
movement of the pin is registered by a computer and the
TEG trace is generated [26,27]. The TEG trace graphically
depicts different stages of the hemostatic process; clotting
time, kinetics, strength and lysis (*See Figure 2) [26,27].
The TEG maximal amplitude (MA) depicts the maximal
strength of the clot, and MA values above or equal to 69
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Multiplate aggregometry
Because of the generation of thrombin secondary to the
kaolin (a very potent initiator of coagulation) activation
in the TEG assay, the effects of antithrombotic agents
such as aspirin (acetylsalicylicacid), non-steroid anti-
inflammatory drugs (NSAID), and ADP-receptor inhibi-
tors, such as clopidogrel, cannot be evaluated. Therefore,
the effects of aspirin and clopidogrel on platelet inhib-
ition are evaluated by Multiplate impedance aggregome-
try (Multiplate, Dynabyte Medical, Munich, Germany).
The assay consists of two silver-coated copper electrodes
immersed in a whole blood sample [28]. The assay is based
on the principle that platelets are non-thrombogenic in a
resting state. Upon admission of specific receptor agonists,
the platelets will begin to adhere to the electrodes, if the
receptors are not blocked by medication. As the platelets
adhere to the electrodes, the resistance between the elec-
trodes will increase and the impedance is registered by a
computer [28]. If addition of ADP to a clopidogrel-treated
patient sample does not trigger any significant adherence
of platelets to the electrodes, this means the drug is suc-
cessfully blocking the ADP-receptors. If addition of ADP
does trigger platelet adhesion, the patient’s ADP receptors
are not successfully blocked by clopidogrel. The results of
this assay are shown to correlate with the development of
thrombotic complications in PCI patients [21]. This assay
has been validated against light transmission aggregome-
try, which is the “gold standard” in platelet aggregation
assays [28].
In the present study, we use the following platelet ago-
nists: ADP (testing for clopidogrel effect), ASPI (arach-
noid acid, testing for aspirin effect) and TRAP (thrombin
receptor-activating peptide, testing for maximum re-
sponse of platelets) [28].
Multislice computed tomography (MSCT)
MSCT technology is rapidly evolving in cardiac imaging.
MSCT allows for assessment of cardiac structures with
high spatial and temporal resolution. MSCT with 16-
slice and 64-slice scanners has been validated for asses-
sing graft patency after CABG [29-31]. Radiation expos-
ure with the evolvement of scanners and scanner
software is brought to a minimum, and is now compar-
able with the radiation exposure of a standard cardiac
angiography [30]. The first 25 patients were scanned
with a 64-slice scanner (Toshiba Aquilion 64, Tokyo,
Japan); due to an upgrade of the scanner, the rest of the
patients included are scanned using a 320-slice scanner
(Toshiba Aquilion ONE, Tokyo, Japan). The scanning
protocol is as follows: gantry rotation time 350 ms, de-
tector collimation 0.5 x 320. Tube voltage and currentare chosen based on the patient’s body mass index ran-
ging between 100 and 120 kV, and mA between 280 and
500. An intravenous contrast media (Visipaque 320 mg
I/ml, GE Healthcare, Buckinghamshire, UK) is infused
using a flow rate of 6 ml/s followed by a saline chaser.
The contrast dye volume used is individually calculated
according to patient body mass index (100 to 130 ml).
Image interpretation is performed using commercially
available software (Vitrea, version 3.0.1, Vital Images,
Minnetonka, Minnesota, USA). Grafts are evaluated by
two experts in cardiac MSCT these are blinded to
patients coagulation and randomization status in the
trial.
Sample size
All patients receive a pedicled left internal thoracic artery
graft at our institution; therefore, every patient on aver-
age will receive an additional two SVGs. Graft patency
for SVGs is approximately 90% after one year. Under the
assumption that TEG-Hypercoagulable patients have a
lower SVG patency of 80%, and that dual antiplatelet
therapy will raise the graft patency of these patients to
the rate in uncomplicated patients (90%), calculations
based on the Fischer exact test with 80% power and 5%
significance level, show the following:
Improvement of graft patency from 80% to 90%: 219 grafts
per group
With an average of 2 SVGs per patient; 219/2 = 110
patients in each group.
We will include 125 patients in each group to account
for “drop-outs” and be able to detect at a significance
level of 5% or better.
Data collection
Preoperatively, during surgery, at Days 3 to 5 after sur-
gery, at discharge and then again three months after sur-
gery, data are collected and entered in the case report
form (CRF). The following data will be collected: demo-
graphic data, past medical history with special emphasis
on cardiac and thromboembolic disease and medication.
Intraoperatively data will also be included, this includes a
description of the quality of SVGs. In-hospital events,
such as MI, stroke and bleeding complications, will be
registered. Throughout the study period, blood compo-
nent transfusion requirements will be registered. The
data are transferred from the CRF to a secure database
by the project coordinator. The local data safety set-up
has been approved of the Danish Data Protection
Agency.
Data and statistical analysis
Results will be included in the final analysis from
patients who have complied with correct intake of study
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Patients, who die during the study period, will be
included in a survival analysis. Patients who must dis-
continue study medication due to a serious adverse event
(SAE) will be followed closely until their condition is
resolved and relevant treatment is completed. SAEs will
be reported to the local health authorities.
Interim analysis will be conducted when 100 TEG-
hypercoagulable patients have been enrolled and under-
gone three-month MSCT.
For categorical variables, χ2 tests or Fisher’s exact test
will be used as appropriate. For continuous variables, ana-
lysis will be performed with the two-sample t-test, after en-
suring normal distribution of the data. Data with no
normal distribution will be analyzed with the Wilcoxon’s
rank-sum test. P-values below 0.05 will be statistically sig-
nificant. Multivariate analyses will be performed, including
both demographic and procedural confounding factors.
Survival analysis will include a Kaplan-Meyer plot.
Ethics and trial registration
The study is conducted in accordance with the Helsinki 2
declaration and has been approved by the Danish Research
Ethics Committee in March 2008 (H-C-2007-0057). The
study is registered at EUDRACT (European Union Drug
Regulating Authorities Clinical Trials) and at clinicaltrials.
gov (Identifier NCT01046942).
Discussion
The evidence for clopidogrel in addition to aspirin after
CABG is divergent, although most studies have not been
able to demonstrate any beneficial effect of dual antipla-
telet therapy. Meanwhile, emerging evidence from obser-
vational studies has demonstrated a significantly higher
thromboembolic risk in both PCI and CABG patients
that are TEG-Hypercoagulable. The TEG-CABG trial is
the first randomized trial to investigate preoperatively
TEG-Hypercoagulable CABG patients. The rationale
being that this is a patient population with a heightened
thromboembolic risk (including graft occlusion) due to
the hypercoagulability, but, hence, also is at low risk for
bleeding on dual antiplatelet therapy. We hypothesize
that this subgroup of CABG patients will benefit the
most on a dual antiplatelet regimen both in regards to
SVG patency and thromboembolic complications in
general.
Examining hemostatic ability and status before and
after surgery/intervention with TEG, we believe will be
the future for postoperative thromboembolic risk evalu-
ation. Including Multiplate aggregometry measurements
in our trial will also help elucidate if resistance measure-
ments after cardiac surgery can help better tailor antipla-
telet regimens. These points become even more
important as the patients referred to cardiac surgery getolder and have more co-morbidities, and, hence, have
limited physiological reserves, where graft occlusions
and even small thromboembolic episodes can have detri-
mental effects on overall health and survival.
Limitations
Due to lack of funding no placebo drug is used, and this
is why the open label design was chosen. However, we
find it plausible to assume that the primary endpoint of
graft patency after three months will not be affected by
the lack of placebo drug in the control group, as the
MSCT evaluators are blinded.
Conclusions
The TEG-CABG trial is the first randomized trial to in-
vestigate whether TEG-Hypercoagulability, before and
after CABG, is predictive of trombembolic events and
death, and if intensified antiplatelet therapy can reduce
this risk. The primary end-point will be SVG patency at
three months postoperatively. The results of this study
may help redefine how patients undergoing coronary
surgery could be evaluated individually in the future for
their postoperative thromboembolic risk, and enable
clinicians to tailor antiplatelet therapy to counter this
risk.
Trial status
Currently 135 patients are randomized in this trial, and
inclusion is ongoing.
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